title: Effect of Cisplatin on the Frequency and Immuno-inhibitory Function of Myeloid-derived Suppressor Cells in A375 Melanoma Model.
abstract: BACKGROUND
  To investigate the change of frequency and immuno-inhibitory function of myeloid-derived suppressor cells (MDSCs) after treatment of cisplatin (DDP) in A375 human melanoma model.
  
  
  METHODS
  BALB/c nude mice were inoculated with A375 cells to establish the human melanoma model and randomly divided into control group given normal saline (NS) and experimental group treated with DDP (5 mg/ kg). The percentages of MDSCs in the tumor tissue and peripheral blood after DDP treatment were detected by flow cytometry. The proliferation and interferon-γ (IFN-γ) secretion of T cells co-cultured with MDSCs were analyzed through carboxyfluorescein succinimidyl ester (CFSE) labeling assay and enzyme-linked immunospot (ELISPOT) assay, respectively.
  
  
  RESULTS
  In A375 human melanoma model, DDP treatment could significantly decrease the percentage of MDSCs in the tumor tissue, but exerted no effect on the level of MDSCs in peripheral blood. Moreover, DDP treatment could attenuate the immuno-inhibitory function of MDSCs. T cells co-cultured with DDP-treated MDSCs could dramatically elevate the proliferation and production of INF-γ.
  
  
  CONCLUSIONS
  DDP can decrease the frequency and attenuate immuno-inhibitory function of MDSCs in A375 melanoma model, suggesting a potential strategy to augment the efficacy of combined immunotherapy.
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China E-mail : yunerni@163.com.
authors.forename: Xiang
authors.initials: X
authors.lastname: Huang
authors.forename: Dan
authors.initials: D
authors.lastname: Guan
authors.forename: Yong-Qian
authors.initials: YQ
authors.lastname: Shu
authors.forename: Lian-Ke
authors.initials: LK
authors.lastname: Liu
authors.forename: Fang
authors.initials: F
authors.lastname: Ni
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D039481:CD11b Antigen / Q000032:analysis; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism / Q000502:physiology; D049109:Cell Proliferation; D002945:Cisplatin / Q000627:therapeutic use*; D018920:Coculture Techniques; D004195:Disease Models, Animal; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007371:Interferon-gamma / Q000378:metabolism; D008546:Melanoma, Experimental / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D022423:Myeloid Cells / Q000737:chemistry / Q000187:drug effects / Q000276:immunology*; D011956:Receptors, Cell Surface / Q000032:analysis
chemical_list: D000970:Antineoplastic Agents; D039481:CD11b Antigen; D011956:Receptors, Cell Surface; C551746:granulocyte receptor 1, mouse; D007371:Interferon-gamma; D002945:Cisplatin